Benitec Ltd is a biotechnology company listed on the Australian Stock Exchange (ASX: BLT). Founded in 1997 to commercialise research from Queensland's Department of Primary Industries (DPI), Benitec is one of the pioneers of RNA interference (RNAi) technology, which can be used to precisely destroy RNA viruses and silence the expression of defective genes. Benitec's ongoing goal is to generate value through the commercialisation of ddRNAi in the area of human therapeutics. The vision is for Benitec to be an internationally competitive company dedicated to the development of treatments for serious human diseases including infectious diseases, neurological disorders, cancer and autoimmune diseases, through leadership in RNAi technologies and strategic partnerships with leading biopharmaceutical companies and research organisations globally.

At Pfizer's new Biotherapeutics and Bioinnovation Center, we're not content waiting to witness the evolution of our industry. Instead, we're driven by science, building on our current successes and capabilities, and playing a critical role in developing the most compelling story of scientific discoveries. And the story continues with the launch of our new RNAi research group. Headquartered at the Research Technology Center (RTC) in Cambridge, MA, and comprising research groups in Cambridge and Düsseldorf, the goal of our RNAi center is clear - delivering RNAi therapies to meet our patient needs and in doing so helping Pfizer become a top tier biotherapeutics company. Our mission is to develop the therapeutic applications of RNAi, and to apply innovative science to solve the difficulties inherent in RNAi therapeutics. Applying our capabilities across a broad range of technologies, our mission combines the best of both worlds - small innovative scientific groups, with the backing of a large pharma.

The company possesses one of the most comprehensive and sophisticated RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercializing RNAi therapeutics. This platform is protected by Silence’s strong intellectual property portfolio which includes more than 200 issued and pending patent applications worldwide. Additionally, Silence is a clear leader in the development of RNAi clinical candidates, possessing a pipeline that includes a total of five different internal and partnered programs in the clinic.  With at least half of the siRNA programs currently in clinical development worldwide based on Silence's technology, the company’s clinical pipeline validates not only the strength of the company's proprietary technology but also the team of researchers that has guided the development path.